Racial Disparities in Melanoma Care: Steps to Improve Care
Premiere Date: Thursday, January 13, 2022This activity offers CE credit for:
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Monday, January 13, 2025
 | Monica E. Peek, MD, MPH, MSc (Moderator) (she/her/hers) Ellen H. Block Professor of Health Justice in the Department of Medicine Associate Director, Chicago Center for Diabetes Translation Research Director of Research, MacLean Center for Clinical Medical Ethics The University of Chicago Chicago, IL |
 | Andrew F. Alexis, MD, MPH Vice-Chair for Diversity and Inclusion Department of Dermatology Weill Cornell Medicine Professor of Clinical Dermatology Weill Cornell Medical College New York, NY |
While melanoma incidence is lower in individuals with darker skin tones, persistent disparities exist in mortality rates, particularly among African American/Black and Hispanic patients. The many factors for higher mortality rates in racial and ethnic minority populations include low public awareness of at-risk populations and a lower index of concern by dermatologists and other clinicians. Additionally, melanoma types that are more common in skin of color are deemed “rare” and typically occur in areas of the body not exposed to UV radiation. Hence, melanoma lesions are more likely to appear in places less frequently surveyed, leading to later diagnoses and worse prognosis. This has led to an education gap in clinicians, particularly in diagnosing and screening practices.
This live CMEO Briefcase will focus on three patients from racial and ethnic minority populations with melanoma and outline best practices for screening to reduce disparities and improve melanoma morbidity and mortality rates in patients of color.
At the end of this CE activity, participants should be able to:
- Implement best practices to improve melanoma morbidity and mortality rates in patients of color.
Supported by an educational grant from the Johnson & Johnson Institute and the Johnson & Johnson Family of Companies.
Physicians, nurse practitioners, PAs, nurses, and pharmacists
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Peek has no disclosures to report.
Dr. Alexis reports that he receives grants from Almirall; Amgen Inc; Arcutis Biotherapeutics; Bristol Myers Squibb; Cara Therapeutics; Dermavant Sciences, Inc.; Galderma; Leo Pharma; Menlo Therapeutics Inc.; Novartis; and Valeant (Bausch Health). He is a consultant for Abbvie Inc.; AllerGen; Almirall; Amgen Inc.; Arcutis Biotherapeutics; Bausch Health; Beiersdorf; Bristol Myers Squibb; Dermavant Sciences, Inc.; Galderma; Janssen; Leo Pharma; L'Oreal; Pfizer Inc.; Sanofi-Regeneron; Sol-Gel Technologies Ltd; UCB; Valeant (Bausch Health); VisualDx; and Vyne Therapeutics. He is on the speakers bureau for Pfizer, Inc; Regeneron; and SANOFI-Genzyme.
Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.
Noreen Iftikhar, MD (planning committee) has no disclosures to report.
Kathleen A. Blake, PhD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
BC-042-011322-57
